ecule inhibitors subsequently designed by a process of rational design. Inhibition of the renin-angiotensin pathway remains one of the cornerstones of cardiovascular medicine, as outlined by recent reviews including those appearing within in this Journal [2] . Interestingly, LCZ696 (Valsartan plus sacubitril), one of the newest cardiovascular drugs of the current era [3] , in addition to inhibiting the enzyme neprilysin targets the same angiotensin pathway.
The phenomenon of ischaemic preconditioning was discovered is 1987, the same year as the Journal was founded, and the two have evolved continuously and in parallel ever since. In this issue, one of the leading researchers in this area, Robert Kloner takes a step back to look at recent progress in this important area, and the exciting new directions with the most potential for moving this field forward [4] .
As populations grow, and environmental effects such as diet, smoking frequency and air pollution evolve, the spectrum and presentation of cardiovascular diseases varies. It is increasingly evident that, despite the impressive benefits of emerging cancer therapies, a substantial proportion of today's successfully-treated cancer patients may become tomorrow's cardiac patient. The group of Prof Derek Yellon of the Hatter Cardiovascular Institute in London, reviews the mechanism of anthracycline cardiotoxicity, and potential methods being developed in order to protect against this injury [5] . This group also offer a review of the topic of cardioprotection in relation to exosomes, endogenous nanoparticles which had only recently been named at the time the Journal began, but which have seen a monumental explosion of interest in recent years [6] .
Thirty years ago mitochondria were primarily regarded purely from the point of view of ATP generation. They are now known to play a central role in cellular survival, and cardiac health and disease, and understanding how their shape and activity is regulated has become a question of major importance. Derek Hausenloy and co-workers examine this rapidly evolving field in their review [7] .
Protein quality control is increasingly recognized as critical in maintaining cellular homeostasis and function. Recent evidence suggests it may be a causal mechanism for the development of atherosclerosis and heart failure. Minamino et al. review the mechanisms of protein quality control and how they may be involved in cardiovascular complications induced not only by anthracyclines, but also by anti-cancer drugs such as tyrosine kinase inhibitors and proteasome inhibitors [8] .
It is hoped that this selection of reviews on key topics illustrates the progress that has been made in cardiovascular research over the past 30 years, and the new areas opening up as a consequence both of changing landscape of disease, and revolutions in research.
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